Naltrexone and Propranolol Combined With Immunotherapy

Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many cells including immune cells and are integral components of the body's response to stress. Pre-clinical studies have demonstrated that dual blockade of these receptors can decrease tumor growth and modulate the anti-tumor immune response. This clinical trial investigates the safety and potential therapeutic benefits of combining a beta-adrenergic blocker (propranolol) and an opioid receptor antagonist (naltrexone)

Trial Details

NCT ID
NCT05968690
Phase
PHASE1
Sponsor
Sarah Weiss
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Propranolol
  • Naltrexone
Locations (sample)
  • New Brunswick, New Jersey, United States|40.48622,-74.45182

Key Eligibility Criteria

  • Age of 18 years or older and able to understand and sign the informed consent form.
  • Histologically confirmed diagnosis of unresectable stage III or stage IV melanoma.
  • Candidate for standard of care therapy with ipilimumab 3 mg/kg + nivolumab 1 mg/kg.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →